Is it possible to develop a “universal” influenza virus vaccine?: Potential for a universal influenza vaccine

Cold Spring Harbor Perspectives in Biology

Volumn 10, Issue 7, 2018, Pages

  Crowe, James E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

HUMAN; IMMUNOLOGY; INFLUENZA;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; HEMAGGLUTININS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN;

EID: 85049518345     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a029496     Document Type: Article

References (37)

1. Avnir Y, Watson CT, Glanville J, Peterson EC, Tallarico AS, Bennett AS, Qin K, Fu Y, Huang CY, Beigel JH, et al. 2016. IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHVutilization shifts and varies by ethnicity. Sci Rep 6: 20842.
2. Bommakanti G, Lu X, Citron MP, Najar TA, Heidecker GJ, ter Meulen J, Varadarajan R, Liang X. 2012. Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge. J Virol 86: 13434–13444.
3. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, et al. 2011. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333: 850–856.
4. DiLillo DJ, Tan GS, Palese P, Ravetch JV. 2014. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat Med 20: 143–151.
5. Eggink D, Goff PH, Palese P. 2014. Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain. J Virol 88: 699–704.
6. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA. 2009. Antibody recognition of a highly conserved influenza virus epitope. Science 324: 246–251.
7. Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, Ophorst C, Cox F, Korse HJ, Brandenburg B, et al. 2011. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333: 843–850.
8. Fu Y, Zhang Z, Sheehan J, Avnir Y, Ridenour C, Sachnik T, Sun J, Hossain MJ, Chen LM, Zhu Q, et al. 2016. A broadly neutralizing anti-influenza antibody reveals on-going capacity of haemagglutinin-specific memory B cells to evolve. Nat Commun 7: 12780.
9. Gauger PC, Vincent AL, Loving CL, Lager KM, Janke BH, Kehrli ME Jr, Roth JA. 2011. Enhanced pneumonia and disease in pigs vaccinated with an inactivated human-like (delta-cluster) H1N2 vaccine and challenged with pandemic 2009 H1N1 influenza virus. Vaccine 29: 2712– 2719.
10. Graves PN, Schulman JL, Young JF, Palese P. 1983. Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: Unmasking of cross-reactive HA2 determinants. Virology 126: 106–116.
11. Hai R, Krammer F, Tan GS, Pica N, Eggink D, Maamary J, Margine I, Albrecht RA, Palese P. 2012. Influenza viruses expressing chimeric hemagglutinins: Globular head and stalk domains derived from different subtypes. J Virol 86: 5774–5781.
12. Harris AK, Meyerson JR, Matsuoka Y, Kuybeda O, Moran A, Bliss D, Das SR, Yewdell JW, Sapiro G, Subbarao K, et al. 2013. Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies. Proc Natl Acad Sci 110: 4592–4597.
13. He W, Tan GS, Mullarkey CE, Lee AJ, Lam MM, Krammer F, Henry C, Wilson PC, Ashkar AA, Palese P, et al. 2016. Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proc Natl Acad Sci doi: 10.1073/pnas.1609316113.
14. Heinen PP, Rijsewijk FA, de Boer-Luijtze EA, Bianchi AT. 2002. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza Avirus. J Gen Virol 83: 1851–1859.
15. Hoa LNM, Mai le Q, Bryant JE, Thai PQ, Hang Nle K, Yen NT, Duong TN, Thoang DD, Horby P, Werheim HF, et al. 2016. Association between hemagglutinin stem-reactive antibodies and influenza A/H1N1 virus infection during the 2009 pandemic. J Virol 90: 6549–6556.
16. Janjua NZ, Skowronski DM, Hottes TS, Osei W, Adams E, Petric M, Sabaiduc S, Chan T, Mak A, Lem M, et al. 2010. Seasonal influenza vaccine and increased risk of pandemic A/H1N1-related illness: First detection of the association in British Columbia, Canada. Clin Infect Dis 51: 1017–1027.
17. Jegaskanda S, Job ER, Kramski M, Laurie K, Isitman G, de Rose R, Winnall WR, Stratov I, Brooks AG, Reading PC, et al. 2013. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol 190: 1837–1848.
18. Jegaskanda S, Reading PC, Kent SJ. 2014. Influenza-specific antibody-dependent cellular cytotoxicity: Toward a universal influenza vaccine. J Immunol 193: 469–475.
19. Kallewaard NL, Corti D, Collins PJ, Neu U, McAuliffe JM, Benjamin E, Wachter-Rosati L, Palmer-Hill FJ, Yuan AQ, Walker PA, et al. 2016. Structure and function analysis of an antibody recognizing all influenza A subtypes. Cell 166: 596–608.
20. Khurana S, Loving CL, Manischewitz J, King LR, Gauger PC, Henningson J, Vincent AL, Golding H. 2013. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Transl Med 5: 200ra114.
21. Krammer F, Pica N, Hai R, Margine I, Palese P. 2013. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 87: 6542–6550.
22. Krammer F, Hai R, Yondola M, Tan GS, Leyva-Grado VH, Ryder AB, Miller MS, Rose JK, Palese P, Garcia-Sastre A, et al. 2014a. Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J Virol 88: 3432–3442.
23. Krammer F, Margine I, Hai R, Flood A, Hirsh A, Tsvetnitsky V, Chen D, Palese P. 2014b. H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J Virol 88: 2340–2343.
24. Lin SC, Lin YF, Chong P, Wu SC. 2012. Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles. PLoS ONE 7: e39075.
25. Lin SC, Liu WC, Jan JT, Wu SC. 2014. Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses. PLoS ONE 9: e92822.
26. Lu Y, Welsh JP, Swartz JR. 2014. Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc Natl Acad Sci 111: 125–130.
27. Monsalvo AC, Batalle JP, Lopez MF, Krause JC, Klemenc J, Hernandez JZ, Maskin B, Bugna J, Rubinstein C, Aguilar L, et al. 2011. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med 17: 195–199.
28. Mullarkey CE, Bailey MJ, Golubeva DA, Tan GS, Nachbagauer R, He W, Novakowski KE, Bowdish DM, Miller MS, Palese P. 2016. Broadly neutralizing hemagglutinin stalk-specific antibodies induce potent phagocytosis of immune complexes by neutrophils in an Fc-dependent manner. MBio 7: e01624–16.
29. Skowronski DM, De Serres G, Crowcroft NS, Janjua NZ, Boulianne N, Hottes TS, Rosella LC, Dickinson JA, Gilca R, Sethi P, et al. 2010. Association between the 2008–09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: Four observational studies from Canada. PLoS Med 7: e1000258.
30. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, Garcia-Sastre A, Palese P. 2010. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 1: e00018–10.
31. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, et al. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16: 265–273.
32. Tran EE, Podolsky KA, Bartesaghi A, Kuybeda O, Grandi-netti G, Wohlbold TJ, Tan GS, Nachbagauer R, Palese P, Krammer F, et al. 2016. Cryo-electron microscopy structures of chimeric hemagglutinin displayed on a universal influenza vaccine candidate. MBio 7: e00257.
33. Vincent AL, Lager KM, Janke BH, Gramer MR, Richt JA. 2008. Failure of protection and enhanced pneumonia with a US H1N2 swine influenza virus in pigs vaccinated with an inactivated classical swine H1N1 vaccine. Vet Microbiol 126: 310–323.
34. Whittle JR, Wheatley AK, Wu L, Lingwood D, Kanekiyo M, Ma SS, Narpala SR, Yassine HM, Frank GM, Yewdell JW, et al. 2014. Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages. J Virol 88: 4047–4057.
35. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, et al. 2011. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208: 181–193.
36. Xu R, Krause JC, McBride R, Paulson JC, Crowe JE Jr, Wilson IA. 2013. A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin. Nat Struct Mol Biol 20: 363–370.
37. Yassine HM, Boyington JC, McTamney PM, Wei CJ, Kanekiyo M, Kong WP, Gallagher JR, Wang L, Zhang Y, Joyce MG, et al. 2015. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med 21: 1065–1070.